文献速递乳腺癌头颈与中枢神经肿瘤

乳腺癌脑转移患者治疗模式与结局:多中心登记研究

Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry.
PubMed 文献 · Eur J Cancer · 2018-08-09

该研究分析了2000年1月至2016年12月间80家机构1712例乳腺癌脑转移患者的临床数据。中位总生存期为7.4个月,HER2阳性、luminal样和三阴性亚型的中位OS分别为11.6、5.9和4.6个月。接受抗HER2治疗的HER2阳性患者中位OS长于未接受者(17.1个月 vs 7.2个月)。

要点

  • 乳腺癌脑转移总体中位OS为7.4个月,1年生存率37.7%。
  • HER2阳性患者中位OS最长(11.6个月),三阴性最短(4.6个月)。
  • HER2阳性患者接受抗HER2治疗者中位OS优于未接受者(17.1 vs 7.2个月)。

核心结论

  • 乳腺癌脑转移患者预后因亚型而异,三阴性和HR阳性/HER2阴性患者结局相似且较差,亟需改进治疗和预防策略。

研究设计与样本

  • 多中心登记研究,分析2000年1月至2016年12月间80家机构1712例乳腺癌脑转移患者的临床数据。

主要发现

  • 脑转移诊断中位年龄56岁(范围22-90岁)。
  • HER2阳性占47.8%(n=732),三阴性占21.4%(n=328),HR阳性/HER2阴性(luminal样)占30.8%(n=471)。
  • 2000-2009年与2010-2015年相比,HER2阳性脑转移比例从51%降至44%,luminal样从28%升至34%(p=0.0331)。
  • 后颅窝脑转移患者中HER2阳性比例(53.8%,169/314)高于三阴性(20.7%,65/314)和luminal样(25.5%,80/314)(p<0.0001)。
  • 总体中位OS为7.4个月(95%CI 6.7-8.0),1年生存率37.7%(95%CI 35.2-40.1)。

关键数值与推荐

  • HER2阳性中位OS 11.6个月(95%CI 10.0-13.4),luminal样5.9个月(95%CI 5.0-7.2),三阴性4.6个月(95%CI 3.9-5.4)。
  • HER2阳性患者接受抗HER2治疗者中位OS 17.1个月,未接受者7.2个月(p<0.0001)。

临床怎么用

  • 乳腺癌脑转移患者应按亚型评估预后,HER2阳性者应接受抗HER2治疗以改善生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Brain metastases (BMs) have a major impact on life expectancy and quality of life for many breast cancer patients. Knowledge about treatment patterns and outcomes is limited. METHODS: We analysed clinical data of 1712 patients diagnosed with BMs from breast cancer between January 2000 and December 2016 at 80 institutions. RESULTS: Median age at diagnosis of BMs was 56 years (22-90 years). About 47.8% (n = 732) of patients had HER2-positive, 21.4% (n = 328) had triple-negative and 30.8% (n = 471) had hormone receptor (HR)-positive, HER2-negative (luminal-like) primary tumours. The proportion of patients with HER2-positive BMs decreased comparing the years 2000-2009 with 2010-2015 (51%-44%), whereas the percentage of patients with luminal-like tumours increased (28%-34%; p = 0.0331). Patients with BMs in the posterior fossa were more often HER2 positive (n = 169/314, 53.8%) than those diagnosed with triple-negative (n = 65/314, 20.7%) or luminal-like primary breast cancer (n = 80/314, 25.5%), (p < 0.0001). Median overall survival (OS) time after development of BMs for the overall cohort was 7.4 months (95% confidence interval [CI]: 6.7-8.0 months). One-year survival rate was 37.7% (95% CI: 35.2-40.1). Patients with HER2-positive tumours had the longest median OS of 11.6 months (95% CI: 10.0-13.4) compared with 5.9 months (95% CI: 5.0-7.2) for patients with luminal-like and 4.6 months (95% CI: 3.9-5.4) for patients with triple-negative tumours. Patients with HER2-positive tumours who received anti-HER2 treatment had longer median OS than those without (17.1 months versus 7.2 months, p < 0.0001). CONCLUSIONS: Prognosis of patients after developing BMs varies significantly according to the subtype. The outcome in this cohort is similarly poor in triple-negative and HR-positive/HER2-negative patients. Our results underline the high medical need for improvement of treatment and prevention strategies for BMs in breast cancer patients.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Witzel I, Laakmann E, Weide R, et al. Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry. Eur J Cancer. 2018. PMID: 30099223. doi:10.1016/j.ejca.2018.07.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。